Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

4 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate

ABSTRACT: We performed a proteomic study, using CD83 overexpression, CD83 knockdown, and control SKOV3 cells by IBT Quantification Proteomics.

ORGANISM(S): Homo Sapiens

SUBMITTER: Suren Chen

PROVIDER: PXD013433 | iProX | Wed Apr 10 00:00:00 BST 2019

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate.

Batool Aalia A Liu Hao H Liu Yi-Xun YX Chen Su-Ren SR

Cancers 20200813 8

Ovarian cancer is a leading cause of death from gynecologic malignancies worldwide. Although CD83 is widely described as a solid marker for mature dendritic cells, emerging pieces of evidence indicate the expression of membrane protein CD83 by various tumor cells, including ovarian cancer cells. However, the potential role of CD83 in ovarian cancer cell properties and development remains absolutely unknown. By using human CD83 stable overexpression and knockdown sublines of several ovarian cance ...[more]

PMID: 32823589

Similar Datasets

CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate.

Project description: Not available

| S-EPMC7465057 | biostudies-literature

Hedgehog signaling pathway in ovarian cancer.

Project description: Not available

| S-EPMC3565315 | biostudies-other

MicroRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-Versican pathway

Project description:Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer. MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in gene regulation and their dysregulation is associated with many diseases. In this study, we determined the expression and function of miR-590-3p in EOC. We found that miR-590-3p levels were higher in high-grade carcinoma when compared to low-grade or tumours with low malignant potential. Interestingly, plasma levels of miR-590-3p were significantly higher in EOC patients than in subjects with benign gynaecological disorders. Transient transfection of miR-590-3p mimics, or stable transfection of mir-590, increased cell growth, migration, and invasion. In vivo studies revealed that mir-590 accelerated tumour growth and metastasis. Using a cDNA microarray, we identified Forkhead box A2 (FOXA2) and Versican (VCAN) as a top downregulated and a top upregulated gene, respectively, by mir-590. We showed that miR-590-3p targeted FOXA2 3’ UTR to suppress its expression. In addition, knockdown of FOXA2 by siRNAs or knockout of FOXA2 by CRISPR/Cas9 enhanced cell proliferation, migration, and invasion. Overexpression of FOXA2 decreased, while knockout of FOXA2 increased, VCAN mRNA and protein levels and ChIP-qPCR revealed that FOXA2 binds to VCAN promoter. Interrogation of the TCGA ovarian cancer database revealed a negative relationship between FOXA2 and VCAN mRNA levels in EOC tumours and that high FOXA2/low VCAN mRNA levels in tumours were positively correlated with patient survival. Finally, overexpression of FOXA2 or silencing of VCAN reversed the effects of mir-590. These findings demonstrate that miR-590-3p promotes EOC development via a novel FOXA2-VCAN pathway.

2018-04-21 | GSE113440 | GEO

Ovarian cancer cell line LC-MS-MS

Project description:A2780-DR cells are cisplatin resistance compared to A2780. H19 knockdown in A2780-DR cells resulted in recovery of cisplatin sensitivity in vitro and in vivo. To demonstrate how H19 contributes to cisplatin-resistance in ovarian cancer, proteomic analysis was carried out on A2780, A2780-DR, A2780-DR/H19si, and A2780-DR/control cells. Proteins expression levels were identified and quantified using MaxQuant software (http://medusa.biochem.mpg.de/maxquant_doku/). The experiments were repeated twice and the false-positive rate was set to be <1%. Based on label-free quantification intensity ratios (>1.67 or <0.6) in proteins that have two or more unique peptides.

2018-10-25 | PXD003252 | Pride

The Role of CD83 in ovarian cancer cell line SKOV3

Project description:We performed RNA-Seq of CD83 overexpression SKOV3 cells (OV_1, OV_2, OV_3), CD83 knockdown SKOV3 cells (KD_1, KD_2, KD-3), and control SKOV3 cells (NC_1, NC_2, NC_3) using BGISEQ-500 platform (BGI, China).

2019-01-14 | GSE125011 | GEO

PLAG1 silencing promotes cell chemosensitivity in ovarian cancer via the IGF2 signaling pathway.

Project description: Not available

| S-EPMC7015041 | biostudies-literature

CtBP determines ovarian cancer cell fate through repression of death receptors.

Project description: Not available

| S-EPMC7181866 | biostudies-literature

Expression and functional pathway analysis of nuclear receptor NR2F2 in Ovarian cancer

Project description:Analysis of NR2F2 knockdown at whole genome level Total RNA isolated 48 hours after NR2F2 knockdown with siRNA compared to siRNA with non-targeting control

2013-05-29 | E-GEOD-47438 | biostudies-arrayexpress

MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/?-catenin signaling pathway.

Project description: Not available

| S-EPMC4745698 | biostudies-other

Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/?-catenin signaling pathway.

Project description: Not available

| S-EPMC4172779 | biostudies-literature